CHRM2 blocking peptide

CHRM2 Blocking Peptide

Cat. Num. AAA9625077

• Gene Names: CHRM2; HM2
• Applications: Blocking/Control
• Purity: The purity is >90%,tested by HPLC and MS.
• Synonyms: CHRM2; CHRM2 Blocking Peptide; 7TM receptor; Acetylcholine receptor; muscarinic; 2; AChR; Acm2; ACM2_HUMAN; Cholinergic receptor muscarinic 2; Cholinergic receptor; muscarinic 2; cardiac; isoform a; muscarinic 2a; CHRM 2; chrm2a; CM2; FLJ43243; HM 2; HM2; M2; M2 muscarinic receptor; M2-mAChR; MGC120006; MGC120007; Muscarinic acetylcholine receptor M2; Muscarinic M2 receptor; CHRM2 blocking peptide

• Purity/Purification: The purity is >90%,tested by HPLC and MS.
• Form/Format: Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.

• Applicable Applications for CHRM2 blocking peptide: Blocking/Control
• Notes: For phospho antibody, we provide phospho peptide (0.5mg) and non-phospho peptide (0.5mg)
• Preparation and Storage: Maintain refrigerated at 2-8 degree C for up to 6 months. For long term storage store at -20 degree C.

Related Product Information for CHRM2 blocking peptide

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (immunoblot) and immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or immunostaining performed with the neutralized antibody.

NCBI and Uniprot Product Information

• NCBI GI #: 4502817
• NCBI GeneID: 1129
• NCBI Accession #: NP_000730.1
• NCBI GenBank Nucleotide #: NM_000739.2
• UniProt Accession #: P08172; Q4VBK6; Q9P1X9
• Molecular Weight: 51,715 Da
• NCBI Official Full Name: muscarinic acetylcholine receptor M2
• NCBI Official Synonym Full Names: cholinergic receptor, muscarinic 2
• NCBI Official Symbol: CHRM2
• NCBI Official Synonym Symbols: HM2
• NCBI Protein Information: muscarinic acetylcholine receptor M2; 7TM receptor; muscarinic M2 receptor; acetylcholine receptor, muscarinic 2; cholinergic receptor, muscarinic 2, isoform a
• UniProt Protein Name: Muscarinic acetylcholine receptor M2
• Protein Family: Muscarinic acetylcholine receptor
• UniProt Gene Name: CHRM2
• UniProt Entry Name: ACM2_HUMAN

NCBI Description

The muscarinic cholinergic receptors belong to a larger family of G protein-coupled receptors. The functional diversity of these receptors is defined by the binding of acetylcholine to these receptors and includes cellular responses such as adenylate cyclase inhibition, phosphoinositide degeneration, and potassium channel mediation. Muscarinic receptors influence many effects of acetylcholine in the central and peripheral nervous system. The muscarinic cholinergic receptor 2 is involved in mediation of bradycardia and a decrease in cardiac contractility. Multiple alternatively spliced transcript variants have been described for this gene. [provided by RefSeq, Jul 2008]

Uniprot Description

mAChR M2: The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Genetic variations in CHRM2 can influence susceptibility to major depressive disorder (MDD). MDD is one of the most common psychiatric disorders. MDD is a complex trait characterized by one or more major depressive episodes without a history of manic, mixed, or hypomanic episodes. A major depressive episode is characterized by at least 2 weeks during which there is a new onset or clear worsening of either depressed mood or loss of interest or pleasure in nearly all activities. Four additional symptoms must also be present including changes in appetite, weight, sleep, and psychomotor activity; decreased energy; feelings of worthlessness or guilt; difficulty thinking, concentrating, or making decisions; or recurrent thoughts of death or suicidal ideation, plans, or attempts. The episode must be accompanied by distress or impairment in social, occupational, or other important areas of functioning. Belongs to the G-protein coupled receptor 1 family. Muscarinic acetylcholine receptor subfamily. CHRM2 sub-subfamily.

Protein type: Membrane protein, integral; Membrane protein, multi-pass; Receptor, GPCR; GPCR, family 1

Chromosomal Location of Human Ortholog: 7q31-q35

Cellular Component: postsynaptic membrane; integral to plasma membrane; plasma membrane; cell junction

Molecular Function: G-protein coupled acetylcholine receptor activity

Biological Process: G-protein signaling, coupled to cAMP nucleotide second messenger; nervous system development; G-protein coupled receptor protein signaling pathway; G-protein signaling, coupled to cyclic nucleotide second messenger; elevation of cytosolic calcium ion concentration during G-protein signaling, coupled to IP3 second messenger (phospholipase C activating); acetylcholine receptor signaling, muscarinic pathway; response to virus; regulation of heart contraction; muscarinic acetylcholine receptor, phospholipase C activating pathway